Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiome transplantation in decompensated cirrhosis
2023-509151-13-00Phase 3Authorised
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Jul 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Allogeneic fecal microbiota capsules with Placebo capsules (2 arms). Primary endpoint: Time to first decompensation event. Planned start Jul 2025; status: authorised.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2023-509151-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509151-13-00.